Xelleratherapeutics · Newsroom
Xellera Therapeutics Expands Cell Sorting Solutions for Advanced Therapy Development
Xellera Therapeutics is expanding its cell sorting solutions to support advanced therapy development. Research teams need accurate tools to isolate and analyze cells.
June 30, 2026
Pharmacopeia Compliance: A Key Pillar in Ensuring Safe and Effective Medicines
Pharmacopeia refers to an official collection of standards and guidelines that define the quality, purity, strength, and consistency of pharmaceutical substances and products.
March 31, 2026
Advancing Regenerative Medicine with MSC Manufacturing Solutions
MSC (Mesenchymal Stem Cells) are multipotent cells used in regenerative medicine for tissue repair, immune modulation, and advanced therapeutic applications.March 20, 2026
GMP Standards Strengthen the Future of Biopharmaceutical Manufacturing
GMP standards ensure quality, safety, and compliance in biopharma manufacturing, protecting patients and supporting advanced therapy innovation.
February 24, 2026
Advanced Therapy Products Driving the Next Era of Innovative Healthcare Solutions
Advanced Therapy Products are transforming modern medicine through innovative cell and gene-based treatments that target diseases at their source and improve patient outcomes.January 1, 2026
Understanding Endotoxins: Why They Matter in Biopharmaceutical Manufacturing
Discover why controlling endotoxins is critical in biopharmaceutical manufacturing. Learn how contamination risks impact safety, quality, and global regulatory compliance.November 26, 2025
Advancing Biopharma Safety and Longevity with Next-Generation Cryogenic Storage Solutions
Cryogenic storage plays a vital role in preserving cell and gene therapy materials, ensuring product stability and safety.October 22, 2025
Dendritic Cells: Pioneering the Next Generation of Immunotherapy and Vaccine Development
Dendritic cells are key immune messengers that activate T-cells to fight cancer, infections, and autoimmune diseases.September 25, 2025
Xellera Therapeutics Advances Diagnostic and Therapeutic Solutions for Mycoplasma pneumoniae
Mycoplasma pneumoniae is a common bacterial pathogen that causes respiratory infections, including atypical pneumonia. It primarily affects children and young adults and can be challenging to treat due to antibiotic resistance.August 21, 2025
Advances Molecular Diagnostics with Enhanced Polymerase Chain Reaction (PCR) Technology
Xellera Therapeutics introduces an advanced Polymerase Chain Reaction (PCR) platform to improve molecular diagnostics.July 14, 2025
Xellera Therapeutics Achieves New GMP Milestone to Advance Quality and Compliance in Therapeutic Manufacturing
Good Manufacturing Practice (GMP) ensures the consistent production and quality of pharmaceuticals and biologics by adhering to rigorous regulatory standards.June 25, 2025